Molecular Testing

Industry analysts predict that molecular testing will continue to grow by over 20% annually in the coming years. Since repeat esoteric tests are often necessary to diagnose, monitor, and determine the success of treatment of diseases such as cancer, HIV, hepatitis, and sexually-transmitted infections, the demand for high-margin molecular tests requiring advanced reagents, sophisticated instruments, and well-trained technicians is escalating rapidly and increasing profit margins within the segment.

Colaborate has been retained to assist numerous organizations in the assessment and development of their potential in this rapidly developing field.